Open Access Open Access  Restricted Access Subscription Access

A COMPLETE EXAMINATION OF THE SPECIFIC DRUG DELIVERY SYSTEM

Miss. Harsha D. Patil, Mr. Akash S. Jain, Mr. Divakar. R. Patil, Mr. Azam Z. Shaikh, Mr. Sameer R. Shaikh, Dr. Sunil P Pawar

Abstract


Since the eyes are protected by a special architecture and physiology, the transport of medications administered using conventional dosage forms is restricted to the eye, and therapeutic drug concentrations in the target tissues are not sustained for an extended period of time. Various droppable items to extend the retention duration on the ocular surface have been introduced to the market for the treatment of the anterior portion of the eye. For the treatment of chronic vitreoretinal disorders, direct intravitreal implants made of biodegradable or non-biodegradable polymers have been extensively studied. The development of ocular drug delivery systems that provide controlled release is urgently required for the treatment of chronic diseases. and promote patient and physician convenience while lowering the frequency of dosage and intrusive treatment. This article reviews the development of ocular medication delivery systems that are now through clinical trials and late stages of experimentation.


Full Text:

PDF

References


Gan, L.; Wang, J.; Jiang, M.; Bartlett, H.; Ouyang, D.; Eperjesi, F.; Liu, J.; Gan, Y. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov. Today 2013, 18, 290–297.

Le Bourlais, C.; Acar, L.; Zia, H.; Sado, P.A.; Needham, T.; Leverge, R. Ophthalmic drug delivery systems—Recent advances. Prog. Retin. Eye Res. 1998, 17, 33–58

Achouri, D.; Alhanout, K.; Piccerelle, P.; Andrieu, V. Recent advces in ocular drug delivery. Drug Dev. Ind. Pharm. 2013, 39, 1599–1617.

Yellepeddi, V.K.; Palakurthi, S. Recent advances in topical ocular drug delivery. J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther. 2016, 32, 67–82.

Kalhapure, R.S.; Suleman, N.; Mocktar, C.; Seedat, N.; Govender, T. Nanoengineered drug delivery systems for enhancing antibiotic therapy. J. Pharm. Sci. 2015, 104, 872–905.

Sharma, S. Antibiotic resistance in ocular bacterial pathogens. Indian J. Med. Microbiol. 2011, 29, 218–222.

Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev, 58, 2006, 1131–35

Jtirvinena K, Tomi J, Urttia SA. Ocular absorption following topical delivery. Adv Drug Deliv Rev, 16, 1995, 3-19

Nanjawade BK, Manvi FV, Manjappa AS. In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release, 122, 2007, 119–34. 14

Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye diseases. Invest Opthalmol Vis Sci 2000; 41: 961-64.


Refbacks

  • There are currently no refbacks.